Patient: 67 years – Male diagnosed with Well-Differentiated Adenocarcinoma of Stomach
Clinical Testing:
- Alterations: S285*, W129S
- Gene: PALB2, PRF1
Treatment Options: Various pre-clinical and clinical trials are evaluating the response of PARP inhibitors in gastric cancers, both as a single agent or in combination with chemotherapy or vascular angiogenic blockers (Ramucirumab). Safety / adverse drug reactions have been evaluated for Olaparib plus Paclitaxel and in Olaparib plus Cisplatin combination therapies.
Indication: The patient was diagnosed with Well-Differentiated Adenocarcinoma of Stomach previously treated with Oxaliplatin and Leucovorin.
Research Findings: The tumor is positive for pathogenic mutation in PALB2 and PRF1. The PALB2 gene mutation is likely of germline origin and warrants the screening of immediate family members related by blood for the inheritance of the same (which can predispose to cancers of breast, ovaries, prostate, etc). PRF1 gene mutations also have been known to predispose formative cancer cells to immune evasion and metastasis.